Find Paid Clinical Trials in Connecticut

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Connecticut

Top of Directory » All Locations » United States » Connecticut




  • Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

    Condition:   Lung Cancer, Stage IIIb or IV
    Intervention:   Other: CHESS website for lung cancer patient + internet access if needed
    Sponsors:   University of Wisconsin, Madison;   Harry Gray Cancer Center Hartford Hospial;   M.D. Anderson Cancer Center;   University of Illinois;   University of Wisconsin Carbone Cancer Center
    Not yet recruiting - verified November 2009

  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • The Effects of Physiologic Oxygen Tension on Clinical In Vitro Fertilization Outcomes

    Conditions:   Pregnancy;   Infertility
    Interventions:   Procedure: Atmospheric oxygen tension;   Procedure: Physiologic oxygen tension
    Sponsors:   Yale University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   University of Pennsylvania;   University of California, San Francisco;   University of Michigan;   Wayne State University
    Not yet recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

    Condition:   Alzheimer Disease
    Intervention:   Drug: MNI-513-01
    Sponsor:   Institute for Neurodegenerative Disorders
    Recruiting - verified October 2009

  • Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders

    Condition:   Alcohol Reactivity
    Interventions:   Drug: varenicline;   Drug: placebo
    Sponsor:   Yale University
    Recruiting - verified October 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • A Weight Loss Study in Overweight Men and Women

    Condition:   Obesity
    Interventions:   Drug: LY377604;   Drug: Sibutramine;   Drug: Metoprolol XL;   Drug: Placebo sibutramine;   Drug: Placebo Metoprolol XL;   Drug: Placebo LY377604
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

    Condition:   Healthy Volunteers
    Interventions:   Drug: PF-04308515;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified October 2009

  • A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: tocilizumab;   Drug: placebo;   Drug: NSAIDs, corticosteroids, methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

    Conditions:   Alzheimer's Disease;   Huntington Disease
    Interventions:   Drug: Dimebon IR Tablet;   Drug: Dimebon MR1;   Drug: Dimebon MR2;   Drug: Dimebon MR3;   Drug: Dimebon MR4
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)

    Condition:   Atrial Fibrillation
    Interventions:   Drug: Vernakalant;   Drug: Placebo
    Sponsors:   Astellas Pharma Inc;   Cardiome Pharma
    Recruiting - verified November 2009

  • RELIEF: Healthcase Utilization and Outcomes of FinESS Treatment in the Office

    Condition:   Rhinosinusitis
    Intervention:   Device: FinESS Sinus Treatment
    Sponsor:   Entellus Medical, Inc.
    Recruiting - verified November 2009

  • A Midazolam Drug Interaction Study With PF-04171327

    Condition:   Healthy Volunteers
    Interventions:   Drug: PF-04171327 25 mg;   Drug: Midazolam 2 mg
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

    Conditions:   Alzheimer's Disease;   Dementia
    Interventions:   Drug: Placebo;   Drug: donepezil (Aricept)
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Nexavar® Versus Placebo in Locally Advance RAI-Refractory Differentiated Thyroid Cancer

    Condition:   Thyroid Neoplasm
    Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
    Sponsors:   Bayer;   Onyx
    Recruiting - verified November 2009

  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: observation
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

    Condition:   Parkinson's Disease
    Interventions:   Drug: IPX066;   Drug: regular carbidopa-levodopa
    Sponsor:   IMPAX Laboratories, Inc.
    Recruiting - verified November 2009

  • Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

    Condition:   Castration-Resistant Prostate Cancer
    Interventions:   Drug: MDV3100;   Drug: Placebo
    Sponsor:   Medivation, Inc.
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain

    Condition:   Sciatica
    Interventions:   Drug: REGN475;   Drug: REGN475;   Drug: Placebo Injection
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi-Aventis
    Recruiting - verified November 2009

  • Safety and Efficacy of F2695 SR in Major Depressive Disorder

    Condition:   Major Depressive Disorder
    Interventions:   Drug: F2695 SR;   Drug: F2695 SR;   Drug: F2695 SR;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting - verified November 2009

  • A Study for Adult Patients With Fibromyalgia

    Conditions:   Fibromyalgia, Primary;   Fibromyalgia, Secondary
    Interventions:   Drug: Duloxetine;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis

    Conditions:   Schizophrenia;   Mental Disorders;   Psychotic Disorders
    Interventions:   Drug: THC and Iomazenil;   Drug: Placebo (control)
    Sponsor:   Yale University
    Recruiting - verified November 2009

  • A Study in Relapse Prevention of Treatment-resistant Depression

    Condition:   Treatment Resistant Depression
    Interventions:   Drug: Olanzapine and Fluoxetine combination;   Drug: Fluoxetine
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

    Conditions:   Obesity;   Overweight;   Healthy
    Interventions:   Drug: PF-04620110;   Drug: Placebo
    Sponsors:   Pfizer;   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

    Condition:   Sarcoma
    Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

    Condition:   Sarcoidosis
    Interventions:   Drug: golimumab;   Drug: ustekinumab;   Drug: Placebo
    Sponsor:   Centocor, Inc.
    Recruiting - verified November 2009

  • Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

    Condition:   Gaucher Disease, Type 1
    Intervention:   Drug: velaglucerase alfa
    Sponsor:   Shire Human Genetic Therapies, Inc.
    Available - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: AZD1152;   Drug: LDAC;   Drug: AZD1152 + LDAC
    Sponsor:   AstraZeneca
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: liraglutide;   Drug: placebo;   Drug: liraglutide;   Drug: placebo
    Sponsor:   Novo Nordisk
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)

    Conditions:   Bipolar Disorder;   Depression
    Intervention:   Drug: PF-04455242
    Sponsor:   Pfizer
    Recruiting - verified October 2009

  • Clazosentan in Aneurysmal Subarachnoid Hemorrhage

    Condition:   Aneurysmal Subarachnoid Hemorrhage
    Interventions:   Drug: Clazosentan;   Drug: Clazosentan;   Drug: Placebo
    Sponsor:   Actelion
    Recruiting - verified November 2009

  • Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

    Condition:   Bronchiectasis
    Interventions:   Drug: Cipro (Ciprofloxacin, BAYQ3939);   Drug: Placebo
    Sponsors:   Bayer;   Novartis
    Recruiting - verified November 2009

  • Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

    Condition:   Raynaud Disease
    Interventions:   Drug: 0.9% nitroglycerin in TAM cream;   Drug: vehicle cream
    Sponsor:   MediQuest Therapeutics
    Recruiting - verified November 2009

  • A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

    Condition:   Overactive Bladder
    Interventions:   Drug: Fesoterodine;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye

    Condition:   Dry Eye
    Interventions:   Drug: SAR 1118;   Drug: Placebo
    Sponsor:   SARcode Corporation
    Recruiting - verified November 2009

  • Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)

    Condition:   Healthy Volunteers
    Interventions:   Drug: Lersivirine;   Drug: Rifabutin;   Drug: Lersivirine;   Drug: Rifabutin
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009

  • A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

    Conditions:   Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
    Interventions:   Biological: Denosumab;   Biological: Placebo
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials